Treatment status of renal cell carcinoma: Renal cancer accounts for 2%~3% of all new cases of tumors worldwide, and nearly 100,000 patients die of renal cancer every year. In China, renal cancer is a malignant tumor in the genitourinary system with an incidence rate second only to bladder cancer. The incidence rate of renal cancer in the world is increasing at an average rate of 2.5% per year, and nearly one-third of the patients with renal cancer have already had distant metastases at the time of diagnosis and are unable to undergo surgical radical treatment. Although surgical resection can cure most of the early stage patients, the recurrence rate after surgery is still as high as 20%~40%, and the metastatic sites of kidney cancer are lymph nodes, lungs, bones, brain and other organs. The prognosis of metastatic renal cancer is quite poor, with a median survival period of 6-12 months and a 5-year survival rate of less than 10%. Therefore, the treatment of metastatic renal cancer is still a major clinical challenge. Since renal cancer cells are not sensitive to cytotoxic drugs and radiotherapy, immunotherapy has long been the main therapeutic tool. In a clinical trial using high-dose interleukin 2 (IL-2), it was found that the treatment significantly prolonged the survival (>18 months) of patients whose tumors went into remission after treatment (14%). However, the severe adverse effects associated with high-dose interleukin-2 therapy have prevented its widespread clinical use, while the results of clinical trials using low-dose IL-2 and interferon (IFN) have been unsatisfactory. Therefore, high-dose IL-2 has long been the only FDA-approved treatment option for metastatic renal cancer. In recent years, with the deeper understanding of the biology and molecular pathogenesis of renal cancer, a variety of molecularly targeted therapeutic agents have been introduced, which have achieved remarkable results in the treatment of metastatic renal cancer. However, there are still many uncharted territories that need to be further explored in the targeted therapy of renal cancer. The cost of targeted therapy and immunotherapy is expensive. There are few reports on the treatment of renal cell carcinoma with traditional Chinese medicine. The feasibility of Sun Qing’s TCM treatment in Surgery Department of Jinan Hospital of Traditional Chinese Medicine Tumor dormancy is one of the biological characteristics of malignant tumors, and the long-term existence of dormant cells is one of the root causes of malignant tumors that are difficult to be completely eradicated and the tumors recur and metastasize in distant places. Biologically, dormant tumor cells refer to tumor cells in the G0 phase of the cell division cycle, but it has been reported that 7% of tumor cells in dormant metastatic tumors are in apoptosis, whereas apoptotic cells account for only 2% of metastatic tumors in the growth state. In the late stage of tumor progression, tumor cells in lymph nodes and dormant tumor cells in bone marrow may be activated for some reasons, and transfer to other organs through bloodstream, causing secondary tumors. Kidney belongs to the essence of the acquired nature and nurtures the aura of the acquired nature. Kidney sheds the yuan yin and yuan yang, which is the essence of yin and yang of the whole body. If the kidney qi is abundant, the organism has strong ability to resist diseases; if the positive qi is solid, the evil will not be related to it; if the kidney qi encourages the qi and blood of the whole body to flow around and transport the nutrients, the organism will be able to overcome the external evils and fight against the diseases outside. The possible mechanism of applying kidney qi replenishing drugs to treat renal malignant tumors is to increase the time of tumor dormancy period of renal tumor patients and prolong their ability to survive with tumor. The effect may also be exerted through immunomodulatory effects. The application of traditional Chinese medicine to replenish kidney qi in the treatment of renal tumors has the possibility of reducing recurrence, and it is an avenue of treatment for patients after resection of renal tumors, and it is an important measure to prolong the life of patients, and it is more suitable for the Chinese national conditions of a therapeutic method. Author’s introduction: Member of Shandong Province Integrative Urology Committee, Adjunct faculty member of Shandong University of Traditional Chinese Medicine. Email: [email protected];Blog: http://blog.sina.com.cn/sunqing0531(Urologist) Tel: 13869190220